Dr. Madapa Kundranda, a medical oncologist at the Banner Cancer Center in Anderson, Anderson, discusses the front line of therapeutic options for patients with newly diagnosed hepatocellular carcinoma (HCC) who are not candidates for surgery or transplant.
The most common option based on liver and extrahepatic involvement is systemic therapy, says Kundranda. Certain liver-targeted therapies may be used in combination with systemic therapies when the disease is predominantly in the liver, but there are currently 2 FDA-approved agents for frontal treatment of HCC.
Sorafenib (Nekshavar) was approved at the forefront of the FDA on the basis of data from the SHARP trial, which is now over 10 years old. The REFLECT trial led to the approval of Lenatanib (Lenvima) for frontline treatment of HCC, says Kundranda. The trial of CheckMate-040 appeared to be encouraging for levellumab (Opdivo) as a front-line treatment, but data presented to ESMO found that the trial had not met its predetermined target.
Overall, levavinib and sorafenib are the 2 FDA-approved options for the treatment of HCC patients in a first-line setting. However, several clinical trials evaluating different combinations, including the combination of chemotherapists, are currently undergoing forefront of HCC treatment.
For more resources and information on anticancer targeted therapies in hepatocellular carcinoma: http: //targetedonc.com/resource-cente …